Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastrointest Oncol. Apr 15, 2020; 12(4): 405-423
Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.405
Table 2 Patient characteristics after propensity score matching
Total (n = 792)Cetuximab (n = 228)Bevacizumab (n = 564)P value
Age at index date1, years0.923
Median64.064.063.0
Sex, n (%)0.914
Female334 (42.2)92 (40.4)242 (42.9)
Male458 (57.8)136 (59.6)322 (57.1)
Race, n (%)0.905
Black or African American71 (9.0)22 (9.6)49 (8.7)
White549 (69.3)158 (69.3)391 (69.3)
Other race111 (14.0)32 (14.0)79 (14.0)
Missing61 (7.7)16 (7.0)45 (8.0)
Region, n (%)0.620
Northeast185 (23.4)54 (23.7)131 (23.2)
Midwest113 (14.3)26 (11.4)87 (15.4)
South253 (31.9)75 (32.9)178 (31.6)
West158 (19.9)48 (21.1)110 (19.5)
Unknown83 (10.5)25 (11.0)58 (10.3)
Practice type, n (%)<0.001
Academic35 (4.4)035 (6.2)
Community757 (95.6)228 (100)529 (93.8)
Site of disease, n (%)1.000
Colon630 (79.5)180 (78.9)450 (79.8)
Rectum162 (20.5)48 (21.1)114 (20.2)
Group stage at initial diagnosis, n (%)0.763
Stage I9 (1.1)3 (1.3)6 (1.1)
Stage II68 (8.6)18 (7.9)50 (8.9)
Stage III245 (30.9)79 (34.6)166 (29.4)
Stage IV458 (57.8)124 (54.4)334 (59.2)
Unknown12 (1.5)4 (1.8)8 (1.4)
ECOG PS at index date1, 2, n (%)0.379
0197 (24.9)61 (26.8)136 (24.1)
1130 (16.4)30 (13.2)100 (17.7)
2+35 (4.4)6 (2.6)29 (5.1)
Missing430 (54.3)131 (57.5)299 (53.0)
Modified CCI at index date1, 3, n (%)0.861
0650 (82.1)185 (81.1)465 (82.4)
1104 (13.1)32 (14.0)72 (12.8)
234 (4.3)10 (4.4)24 (4.3)
3+4 (0.5)1 (0.4)3 (0.5)
NRAS tested, n (%)274 (34.6)70 (30.7)204 (36.2)0.410
NRAS status among those tested4, n (%)0.908
Mutation negative268 (97.8)68 (97.1)200 (98.0)
Mutation positive000
Results pending1 (0.4)01 (0.5)
Unknown1 (0.4)1 (1.4)0
Unsuccessful/indeterminate4 (1.5)1 (1.4)3 (1.5)
BRAF tested, n (%)290 (36.6)76 (33.3)214 (37.9)0.955
BRAF status among those tested4, n (%)0.881
Mutation negative248 (85.5)64 (84.2)184 (86.0)
Mutation positive39 (13.4)10 (13.2)29 (13.6)
Results pending1 (0.3)01 (0.5)
Unknown1 (0.3)1 (1.3)0
Unsuccessful/indeterminate1 (0.3)1 (1.3)0
First-line chemotherapy backbone, n (%)0.485
FOLFIRI387 (48.9)149 (65.4)238 (42.2)
FOLFOX405 (51.1)79 (34.6)326 (57.8)
History of adjuvant chemotherapy5, n (%)0.789
No/not documented519 (65.5)140 (61.4)379 (67.2)
Yes273 (34.5)88 (38.6)185 (32.8)
First-line therapy duration6, days0.424
Median179.0162.0190.0
Length of follow-up7, days0.533
Median434.0428.5434.5
Side of colon, n (%)0.868
Left side283 (35.7)78 (34.2)205 (36.3)
Rectosigmoid62 (7.8)17 (7.5)45 (8.0)
Rectum154 (19.4)47 (20.6)107 (19.0)
Splenic flexure19 (2.4)5 (2.2)14 (2.5)
Right side231 (29.2)68 (29.8)163 (28.9)
Transverse colon43 (5.4)13 (5.7)30 (5.3)